Stephen C. Knight, M.D. (President, Fidelity Biosciences)


Dr. Knight has worked in the pharmaceutical and biotechnology industries for over sixteen years. Prior to joining Fidelity in 2003, Dr. Knight was president and chief operating officer for EPIX Pharmaceuticals in Cambridge, Massachusetts. For six years before joining EPIX, Dr. Knight worked at Arthur D. Little Inc., primarily as a senior consultant in Cambridge and Brussels, Belgium specializing in mergers and acquisitions in the pharmaceutical industry. Prior to 1990, Dr. Knight performed research at AT&T Bell Laboratories (now Lucent Technologies), the National Institutes of Health, and at Yale University. Dr. Knight holds an M.D. from the Yale University School of Medicine and an M.B.A. from the Yale School of Organization and Management. Dr. Knight received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa. Dr. Knight currently serves as chairman of the Board of Directors for Veritas Medicine and EnVivo Pharmaceuticals. He also serves on the Board of Directors of Microbia, U.S. Genomics, and FoldRx Pharmaceuticals.

Randall Carpenter, M.D. (CEO, Seaside Therapeutics)

Dr. Carpenter is Founder, President and CEO of Seaside Therapeutics, a drug discovery company focused on developing novel therapeutics for disorders of brain development such as Fragile X and autism.Dr. Carpenter has over 25 years experience in medicine, basic science and clinical research, pharmaceutical drug development and management. He has held a number of leadership positions in the pharmaceutical and biotechnology industries including: President and CEO of Sention, Vice-President of Clinical Research & Development and Regulatory Affairs at Adolor Corporation, Director of Clinical Research at Astra USA, and Member of the Global Therapeutic Area Team at Astra Pain Control Sweden.Dr. Carpenter has broad experience leading pharmaceutical research and development teams submitting a number of successful IND’s, NDA’s and sNDA’s.Prior to industry, Dr. Carpenter held academic faculty appointments at the University of Washington and Wake Forest University. Dr. Carpenter has co-authored 65 journal articles and seven patents and has served as editor-in-chief or on the editorial boards of four medical journals.He has frequently been an invited speaker at national and international meetings and symposia and has been an invited visiting professor to numerous domestic and international universities and medical schools.Dr. Carpenter is Board Certified in Anesthesiology and Pain Management, completed a fellowship in pharmacokinetics at the University of California San Francisco and a sabbatical in molecular biology at the University of Washington.

C. Thomas Caskey, M.D. (Brown Foundation Institute of Molecular Medicine – Univ. of Texas)

C. Thomas Caskey, M.D., F.A.C.P., is Director and Chief Executive Officer-Elect and Chief Operating Officer of the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), at the University of Texas Health Science Center at Houston. Dr. Caskey was founding director of Houston-based Cogene Biotech Ventures and Cogene Ventures, venture capital funds supporting early-stage biotechnology and life sciences companies. The fund, founded in March 2000, invested in companies that utilize genome technology to enable drug discovery in high growth therapeutic specialties such as cancer, neurology and the metabolic diseases of obesity and diabetes. Dr. Caskey has received numerous academic and industry-related honors. He is a member of the National Academy of Sciences and the Institute of Medicine. He has served as president of American Society of Human Genetics, the Human Genome Organization and The Academy of Medicine, Engineering and Science of Texas (TAMEST). He previously served as senior vice president for human genetics and vaccines discovery at Merck Research Laboratories from 1994 to 2000 and as president of the Merck Genome Research Institute from 1998 to 2000. He received the Distinguished Texas Geneticist Award from the Texas Genetics Society in 1998 and serves on Texas Governor Rick Perry’s Council on Science and Biotechnology, which makes funding recommendations for the $200 million Texas Emerging Technology Fund. Dr. Caskey earned his medical degree from Duke University School of Medicine and his undergraduate degree from the University of South Carolina. He is Board certified in Internal Medicine, Clinical Genetics, Metabolic Diseases and Molecular Diagnostics.

Mark Peterson (Formerly Fidelity Investments)

John Remondi (Fidelity Investments)

Jason Rhodes (Partner, Fidelity Biosciences)

Mr. Rhodes has worked in principal investing and healthcare for 15 years, playing a leading role in a range of venture capital and private equity investments during that time. Prior to joining Fidelity in 2001, Mr. Rhodes was a vice president with MPM Capital and a consultant with Corporate Decisions, Inc., among other positions. His investing experience includes therapeutics, research instruments, diagnostics, biodefense, and healthcare services and IT. His consulting work focused on R&D and product strategy, alliances, and M&A. Specific projects included the clinical trial strategy and global launch of Taxotere, a blockbuster oncology product, a product acquisition strategy for DePuy orthopedics, the $465M Bayer-Millennium target discovery partnership, and the design and restructuring of Wyeth’s sales organization following the acquisition of American Cyanamid. He has a B.A. from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania. He serves on the Board of Directors of Mersana Therapeutics and EnVivo Pharmaceuticals, where he was also previously acting Chief Business Officer, and is an observer on the boards of Microbia, U.S. Genomics, and FoldRx.